Sneha Kesarkar

• Leadership in Market Share and Prescription Share: Managed Vertin, one of Abbott India's leading brands with a 34% market share. Successfully increased market share by 1.3% and prescription share by 2%, maintaining both value and prescription efficiency indexes above 100.
• Therapy Shaping Initiatives: Spearheaded pioneering therapy-shaping initiatives to bridge gaps in the continuum of care, significantly enhancing patient outcomes.
• Market Expansion and Awareness Initiatives: Launched comprehensive awareness initiatives aimed at market expansion, resulting in the recognition of the Best Brand Plan for two consecutive years.
• Digital Innovation in Healthcare: Received awards for digital innovation, including the development of the Vertigo Coach app and the Nystagmus Atlas, which have improved patient education and engagement

• Managed the epilepsy portfolio for the mega brand Eptoin, developing and implementing a patient support program.
• Launched an award-winning patient awareness program for epilepsy, significantly enhancing brand visibility and patient engagement.

• Drove prescription share gain among specialists and implemented various therapy-shaping initiatives, leading to recognition for the Best Brand Plan in 2021.
• Managed the pediatric portfolio for Brand Advent, enhancing brand performance through targeted marketing and strategic initiatives.

• Managed and enhanced the profitability, growth, and image of Nootropil, a leading brand in acute stroke management, with a portfolio worth INR 40 Crores.
• Developed and launched an innovative Patient Support Program, improving stroke rehabilitation recovery and therapy adherence, while analyzing market trends to implement effective marketing strategies.
• Conceptualized and executed programs for Key Opinion Leaders (KOLs), building strong industry relationships, and coordinating with cross-functional teams to develop strategic business plans and promotion pipelines.

• Managed a brand portfolio worth INR 60 Crores, including research brands Atarax and Xyzal, and implemented co-promotion strategies, resulting in a 2.5% market share increase.
• Received the Best Brand Plan Award in 2015 for executing successful brand marketing plans, enhancing sales, market share, and profit margins.
• Organized advisory board meetings with KOLs/KBLs, ensuring compliance with global guidelines, which boosted sales and profitability in India and Nepal

• Handled Dompan range and launched Gutfast, overseeing strategy, execution, and high-impact promotional materials.
• Supervised division activities, including creating advertising and marketing collateral.

GSK Phama as Medical representative
Derma CTT Mumbai